Tempus AI partners with Angiosarcoma Awareness on rare cancer data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro softer after ECB stands pat on rates
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers
June 25, 2026 8:30 AM EDTCHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a research collaboration with Angiosarcoma Awareness, Inc. to accelerate data-driven research in angiosarcoma, one of the rarest and most aggressive cancers. Angiosarcoma is a rare malignant tumor that starts in endothelial cells, which form the inner lining of blood vessels. It is known for its aggressive behavior, rapid progression and poor prognosis, making it a particularly challenging cancer to treat.
The collaboration will leverage Tempus robust datasets... More
